{
    "nctId": "NCT00785291",
    "briefTitle": "Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",
    "officialTitle": "A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-paclitaxel or Ixabepilone With or Without Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive, Progesterone Receptor Negative, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIC Breast Cancer AJCC v6, Stage IV Breast Cancer AJCC v6 and v7",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 799,
    "primaryOutcomeMeasure": "Progression Free Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologic confirmation of invasive cancer of the breast\n* Stage IV disease or stage IIIC disease (using American Joint Committee on Cancer \\[AJCC\\] criteria, 6th edition) not amenable to local therapy\n* Patients may not have a \"currently active\" second malignancy other than non-melanoma skin cancers; patients are not considered to have a \"currently active\" malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse\n* Patients with human epidermal growth factor receptor 2 (HER2) negative disease are eligible; patients with HER2+ disease are eligible providing they have previously received trastuzumab or lapatinib; documentation of progression on HER2 directed therapy is not required; Her2/neu status must be known at the time of protocol registration\n* Estrogen receptor (ER) and progesterone receptor (PgR) status must be known at the time of registration; ER and/or PgR \\>= 1% cells will be considered positive\n* Prior treatment may include adjuvant or neoadjuvant taxane, however, the interval between completion of adjuvant or neoadjuvant therapy and disease recurrence must be \\>= 12 months\n* No prior chemotherapy for metastatic breast cancer\n* Any number of prior hormonal therapies are allowed; the last dose should have been administered at least 7 days prior to the initiation of protocol therapy\n* Prior radiotherapy must be completed at least 2 weeks prior to study entry\n* Treatment with bisphosphonates is allowed and recommended as per American Society of Clinical Oncology (ASCO) guidelines\n* Prior trastuzumab or lapatinib required for patients with HER2 overexpressing tumors\n* Prior treatment with bevacizumab is allowed\n* Patients must not have had a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study registration, and must have fully recovered from any such procedure\n\n  * The following are not considered to be major procedures: thoracentesis, paracentesis, port placement, laparoscopy, thoracoscopy, bronchoscopy, endoscopic ultrasonographic procedures, mediastinoscopy, skin biopsies, incisional biopsies and routine dental procedures\n* Patients must not have anticipation of need for a major surgical procedure during the course of the study\n* There are no restrictions on core biopsies, placement of a vascular access device or other minor procedures prior to registration\n\n  * Placement of a vascular access device after starting study therapy should be performed between day 15 and 28 of a treatment cycle (but not less than 48 hours before the next dose of bevacizumab) to allow for sufficient healing\n* Patients must have measurable disease (target lesions): measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \\>= 2.0 cm with conventional techniques or as \\>= 1 cm with spiral computed tomography (CT) scan\n\n  * Lesions that are considered non-measurable include the following:\n\n    * Bone lesions\n    * Leptomeningeal disease\n    * Ascites\n    * Pleural/pericardial effusion\n    * Inflammatory breast disease\n    * Lymphangitis cutis/pulmonitis\n    * Abdominal masses that are not confirmed and followed by imaging techniques\n    * Cystic lesions\n* Patients with pre-existing peripheral neuropathy \\>= grade 2 are not eligible for this study\n* Patients must have an Eastern Cooperative Oncology Group (ECOG) (Zubrod) performance status of =\\< 1 to be eligible for this trial\n* Women must not be pregnant or breast feeding; premenopausal women must have a negative serum or urine beta-human chorionic gonadotropin (Hcg)\n* Patients with a history of Common Terminology Criteria for Adverse Events (CTCAE) grade \\>= 3 hypersensitivity to paclitaxel or Cremophor\u00ae EL are not eligible\n* Patients with a history of abdominal fistula, or intra-abdominal abscess within 6 months prior to study registration are not eligible\n* Patients with a history of gastrointestinal (GI) perforation within 12 months prior to registration are not eligible\n* Patients with a history of significant bleeding episodes (e.g., hemoptysis, upper or lower GI bleeding) within 6 months prior to registration are not eligible\n* Patients must not have a history of clinically significant cardiovascular disease that includes the following:\n\n  * Uncontrolled hypertension defined as systolic blood pressure \\> 150 and/or diastolic blood pressure \\> 90 mmHg on antihypertensive medications or any prior history of hypertensive crisis or hypertensive encephalopathy\n  * History of myocardial infarction or unstable angina within past 6 months\n  * New York Heart Association (NYHA) congestive heart failure grade 2 or greater\n  * Symptomatic peripheral vascular disease\n  * Significant vascular disease (e.g., aortic aneurysm, aortic dissection) or arterial thrombotic events\n* Patients on full dose anticoagulants must be on a stable dose of warfarin, or be on a stable dose of low molecular weight (LMW) heparin; patients receiving anti-platelet or on daily prophylactic dose aspirin are eligible, as are patients receiving stable doses of anticoagulation for atrial fibrillation\n* Patients may not have a history of stroke or transient ischemic attack within 6 months prior to study registration\n* Patients with a history of seizures must be well controlled with standard medication\n* Patients must not have progressing or untreated central nervous system (CNS) metastases or leptomeningeal disease; patients with a history of resected brain metastases with stable magnetic resonance imaging (MRI) scans for 3 months including within 4 weeks of study start are eligible; patients with a history of gamma knife radiosurgery or whole brain radiation with stable MRI scans for 3 months including within 4 weeks of study start are eligible\n* No serious, non-healing wound, ulcer or bone fracture\n* Life expectancy of \\>= 12 weeks\n* Granulocytes \\>= 1,500/ul\n* Platelet count \\>= 100,000/ul\n* Creatinine =\\< 2.0 mg/dL\n* Bilirubin \\< 1.5 mg/dL (unless due to Gilbert's syndrome)\n* Transaminases (aspartate aminotransferase \\[AST\\], alanine aminotransferase \\[ALT\\]) =\\< 2.5 x upper limit of normal (ULN)\n* Serum or urine beta-Hcg negative in premenopausal women of child-bearing potential\n* Urine protein =\\< 1+ protein\\* or urine protein: creatinine ratio (UPC) \\< 1\n\n  * Patients discovered to have \\>= 2+ proteinuria at baseline must undergo a 24-hour urine collection that must demonstrate \\< 1 g of protein/24 hr or UPC ratio =\\< 1 to allow participation in the study",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}